Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration
Buprenorphine is an opioid drug used in the management of pain and the treatment opioid addiction. Like other opioids, it is believed that it achieves these effects by altering functional neurotransmitter pathways and the expression of important transcription factors; cyclic AMP response element-bin...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332221003000 |
id |
doaj-b42c9fa8e37146f58edcab0afc27107f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sanelisiwe P. Xhakaza Leon J. Khoza Advaitaa M. Haripershad Terisha Ghazi Shanel Dhani Cosmas Mutsimhu Molopa J. Molopa Nithia P. Madurai Lorna Madurai Sanil D. Singh Nirmala D. Gopal Hendrik G. Kruger Thavendran Govender Anil Chuturgoon Tricia Naicker Sooraj Baijnath |
spellingShingle |
Sanelisiwe P. Xhakaza Leon J. Khoza Advaitaa M. Haripershad Terisha Ghazi Shanel Dhani Cosmas Mutsimhu Molopa J. Molopa Nithia P. Madurai Lorna Madurai Sanil D. Singh Nirmala D. Gopal Hendrik G. Kruger Thavendran Govender Anil Chuturgoon Tricia Naicker Sooraj Baijnath Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration Biomedicine & Pharmacotherapy Buprenorphine Opioid addiction Brain-derived neurotrophic factor (BDNF) Cyclic AMP response element-binding protein (CREB) Neurotransmitters |
author_facet |
Sanelisiwe P. Xhakaza Leon J. Khoza Advaitaa M. Haripershad Terisha Ghazi Shanel Dhani Cosmas Mutsimhu Molopa J. Molopa Nithia P. Madurai Lorna Madurai Sanil D. Singh Nirmala D. Gopal Hendrik G. Kruger Thavendran Govender Anil Chuturgoon Tricia Naicker Sooraj Baijnath |
author_sort |
Sanelisiwe P. Xhakaza |
title |
Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration |
title_short |
Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration |
title_full |
Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration |
title_fullStr |
Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration |
title_full_unstemmed |
Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration |
title_sort |
alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration |
publisher |
Elsevier |
series |
Biomedicine & Pharmacotherapy |
issn |
0753-3322 |
publishDate |
2021-06-01 |
description |
Buprenorphine is an opioid drug used in the management of pain and the treatment opioid addiction. Like other opioids, it is believed that it achieves these effects by altering functional neurotransmitter pathways and the expression of important transcription factors; cyclic AMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) in the brain. However, there is a lack of scientific evidence to support these theories. This study investigated the pharmacodynamic effects of BUP administration by assessing neurotransmitter and molecular changes in the healthy rodent brain. Sprague-Dawley rats (150–200 g) were intranasally administered buprenorphine (0.3 mg/mL) and sacrificed at different time points: 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h post drug administration. LC-MS was used to quantify BUP and neurotransmitters (GABA, GLUT, DA, NE and 5-HT) in the brain, while CREB and BDNF gene expression was determined using qPCR. Results showed that BUP reached a Cmax of 1.21 ± 0.0523 ng/mL after 2 h, with all neurotransmitters showing an increase in their concentration over time, with GABA, GLUT and NE reaching their maximum concentration after 8 h. DA and 5-HT reached their maximum concentrations at 1 h and 24 h, respectively post drug administration. Treatment with BUP resulted in significant upregulation in BDNF expression throughout the treatment period while CREB showed patterns of significant upregulation at 2 and 8 h, and downregulation at 1 and 6 h. This study contributes to the understanding of the pharmacodynamic effects of BUP in opioid addiction by proving that the drug significantly influences NT pathways that are implicated in opioid addiction. |
topic |
Buprenorphine Opioid addiction Brain-derived neurotrophic factor (BDNF) Cyclic AMP response element-binding protein (CREB) Neurotransmitters |
url |
http://www.sciencedirect.com/science/article/pii/S0753332221003000 |
work_keys_str_mv |
AT sanelisiwepxhakaza alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT leonjkhoza alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT advaitaamharipershad alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT terishaghazi alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT shaneldhani alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT cosmasmutsimhu alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT molopajmolopa alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT nithiapmadurai alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT lornamadurai alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT sanildsingh alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT nirmaladgopal alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT hendrikgkruger alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT thavendrangovender alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT anilchuturgoon alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT tricianaicker alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration AT soorajbaijnath alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration |
_version_ |
1721434694135840768 |
spelling |
doaj-b42c9fa8e37146f58edcab0afc27107f2021-05-20T07:45:17ZengElsevierBiomedicine & Pharmacotherapy0753-33222021-06-01138111515Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administrationSanelisiwe P. Xhakaza0Leon J. Khoza1Advaitaa M. Haripershad2Terisha Ghazi3Shanel Dhani4Cosmas Mutsimhu5Molopa J. Molopa6Nithia P. Madurai7Lorna Madurai8Sanil D. Singh9Nirmala D. Gopal10Hendrik G. Kruger11Thavendran Govender12Anil Chuturgoon13Tricia Naicker14Sooraj Baijnath15Catalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaDiscipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, 4001, South AfricaDiscipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, 4001, South AfricaViro Care (SA) Pty Ltd, 12 The Avenue East, Prospecton, Durban 4113, South AfricaViro Care (SA) Pty Ltd, 12 The Avenue East, Prospecton, Durban 4113, South AfricaViro Care (SA) Pty Ltd, 12 The Avenue East, Prospecton, Durban 4113, South AfricaViro Care (SA) Pty Ltd, 12 The Avenue East, Prospecton, Durban 4113, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaDepartment of Criminology, University of KwaZulu-Natal, Durban 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaDepartment of Chemistry, University of Zululand, Private Bag X1001, KwaDlangezwa 3886, South AfricaDiscipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South Africa; Corresponding author.Buprenorphine is an opioid drug used in the management of pain and the treatment opioid addiction. Like other opioids, it is believed that it achieves these effects by altering functional neurotransmitter pathways and the expression of important transcription factors; cyclic AMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) in the brain. However, there is a lack of scientific evidence to support these theories. This study investigated the pharmacodynamic effects of BUP administration by assessing neurotransmitter and molecular changes in the healthy rodent brain. Sprague-Dawley rats (150–200 g) were intranasally administered buprenorphine (0.3 mg/mL) and sacrificed at different time points: 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h post drug administration. LC-MS was used to quantify BUP and neurotransmitters (GABA, GLUT, DA, NE and 5-HT) in the brain, while CREB and BDNF gene expression was determined using qPCR. Results showed that BUP reached a Cmax of 1.21 ± 0.0523 ng/mL after 2 h, with all neurotransmitters showing an increase in their concentration over time, with GABA, GLUT and NE reaching their maximum concentration after 8 h. DA and 5-HT reached their maximum concentrations at 1 h and 24 h, respectively post drug administration. Treatment with BUP resulted in significant upregulation in BDNF expression throughout the treatment period while CREB showed patterns of significant upregulation at 2 and 8 h, and downregulation at 1 and 6 h. This study contributes to the understanding of the pharmacodynamic effects of BUP in opioid addiction by proving that the drug significantly influences NT pathways that are implicated in opioid addiction.http://www.sciencedirect.com/science/article/pii/S0753332221003000BuprenorphineOpioid addictionBrain-derived neurotrophic factor (BDNF)Cyclic AMP response element-binding protein (CREB)Neurotransmitters |